Cargando…
Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in clinical practice. Here we investigated the mechanisms underlying acquired bortezomib resistance in hepatocellular carcinoma (HCC) cells. Using stepwise selection, we established two acquired bortezomib-resista...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363609/ https://www.ncbi.nlm.nih.gov/pubmed/27769058 http://dx.doi.org/10.18632/oncotarget.12731 |